<!DOCTYPE html>
<html lang="en">
  <head>
    <meta charset="utf-8" />
    <link rel="icon" href="%PUBLIC_URL%/favicon.ico" />
    <meta name="viewport" content="width=device-width, initial-scale=1" />
    <meta name="theme-color" content="#000000" />
    <meta
      name="description"
      content="Formed in 2012, DeuteRx is a virtual biopharmaceutical company focused on improving racemic drugs for patients. Our team has pioneered the use of Deuterium-Enabled Chiral Switching (DECS) to isolate a single stereoisomer from a mixture of interconverting stereoisomers. This revolutionary strategy stabilizes the preferred stereoisomer in existing drugs sold as racemic mixtures to reduce deleterious side-effects and improve efficacy. We have applied DECS to a wide range of clinical therapies, including the deuterium-stabilized R-stereoisomer of pioglitazone for nonalcoholic steatohepatitis (NASH) (PXL065, acquired by Poxel in 2018) and the deuterium-stabilized S-stereoisomer of lenalidomide (DRX-053, acquired by Celgene in 2012)."
    />
    <link rel="manifest" href="%PUBLIC_URL%/manifest.json" />
    <link
      rel="stylesheet"
      href="https://maxcdn.bootstrapcdn.com/bootstrap/4.3.1/css/bootstrap.min.css"
      integrity="sha384-ggOyR0iXCbMQv3Xipma34MD+dH/1fQ784/j6cY/iJTQUOhcWr7x9JvoRxT2MZw1T"
      crossorigin="anonymous"
    />
    <title>DeuteRx</title>
    <meta name="og:title" property="og:title" content="DeuteRx | Improving Medicines for Patients" />
    <meta
      name="og:description"
      property="og:description"
      content="Formed in 2012, DeuteRx is a virtual biopharmaceutical company focused on improving racemic drugs for patients. Our team has pioneered the use of Deuterium-Enabled Chiral Switching (DECS) to isolate a single stereoisomer from a mixture of interconverting stereoisomers. This revolutionary strategy stabilizes the preferred stereoisomer in existing drugs sold as racemic mixtures to reduce deleterious side-effects and improve efficacy. We have applied DECS to a wide range of clinical therapies, including the deuterium-stabilized R-stereoisomer of pioglitazone for nonalcoholic steatohepatitis (NASH) (PXL065, acquired by Poxel in 2018) and the deuterium-stabilized S-stereoisomer of lenalidomide (DRX-053, acquired by Celgene in 2012)."
    />
    <meta name="og:image" property="og:image" content="%PUBLIC_URL%/deuterx-water-splash.jpg" />
    <meta name="keywords" content="medicine,patients,deuterium,chiral,switching,drug" />
    <meta name="robots" content="index,follow" />
    <link href="https://fonts.googleapis.com/css2?family=Mulish:ital,wght@0,200;0,300;0,400;0,500;0,600;0,700;0,800;0,900;1,200;1,300;1,400;1,500;1,600;1,700;1,800;1,900&display=swap" rel="stylesheet">
    <script src="https://kit.fontawesome.com/0b9f8be31e.js" crossorigin="anonymous"></script>
  </head>
  <body>
    <noscript>You need to enable JavaScript to run this app.</noscript>
    <div id="root"></div>
  </body>
</html>
